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(Reith et al., 2000). About 95% of GISTs and EGISTs express C-Kit recep-
tor (CD117) and CD34 on immunohistochemical staining (Trent and
Benjamin, 2006). Surgery and tyrosine kinase inhibitors are the current
treatment options for these tumors (Trent and Benjamin, 2006). We
previously reported our experiencewith treatingGISTs discovered as in-
cidental ﬁndings in patients with suspected ovarian masses. Here, we
report a case of an EGIST arising in the rectovaginal septum.
Case report
A 15-year-old female, gravida 0, para 0, presented to an orthope-performed, and the ﬁndings were reported as normal. One month
Introduction
Gastrointestinal stromal tumors (GISTs) are themost commonmes-
enchymal tumors of the gastrointestinal tract (Trent and Benjamin,
2006). Sixty percent of GISTs arises from the stomach, 25% from the
small intestine, and 10% from the colon or rectum (Trent and
Benjamin, 2006). The remaining 5% arises from other intraabdominal
locations—for example, the omentum, mesentery, retroperitoneal
space, or urinary bladder (Trent and Benjamin, 2006). GISTs arising
from such atypical sites are called extragastrointestinal stromal tumors
(EGISTs) (Reith et al., 2000). Because EGISTs seldomproduce symptoms,
75% of EGISTs are larger than 10 cm at the time of detection (Reith et al.,
2000). EGISTs arising from the omentum appear to have a betterlogic Oncology, Instituto de
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Inc. Open access under CC BY-NC-ND licensdic surgeon in February 2008 complaining of sudden-onset sacral
pain. The patient's past medical history was unremarkable. The ortho-
pedic physical examination was normal. Lumbar radiography was
later, the patient presented to her pediatrician complaining of consti-
pation. A digital rectal examination was performed, and the ﬁndings
were normal. In May 2008, the patient experienced rectal pressure
and consulted a colorectal surgeon, who palpated a 2-cm rubbery
mass on the impinging on the anterior rectal wall 6 cm from the
anal margin. Rectosigmoidoscopy was performed and conﬁrmed a
2-cm mass compressing the anterior wall of the rectum. The lesion
was completely resected with negative margins via transrectal resec-
tion and sent for pathologic evaluation. There were no complications
associated with the resection.
The gross appearance of the lesion was that of a sarcomatous
tumor; microscopically, the tumor was composed of a proliferation
of mildly pleomorphic spindle cells with elongated nuclei and eosin-
ophilic cytoplasm. Tumor necrosis was present, and up to 40 mitotic
ﬁgures per 50 high-power ﬁelds were identiﬁed (Fig. 1). Immunohis-
tochemical staining demonstrated positive staining for C-Kit protein
(CD117) and DOG 1.1 (discovered on GIST) and negative staining
for CD34, smooth muscle actin, desmin, S-100, h-caldesmon, and a
keratin cocktail (AE1/AE3) (Fig. 2). Margins were reported as nega-
tive. The diagnosis of an EGIST was made.
Treatment with tyrosine kinase inhibitors was recommended be-
cause of the high mitotic rate, but the patient, in consultation with
her family, opted not to undergo adjuvant therapy. Four months
after surgery, in September 2008, the patient presented with a rectale.
Fig. 1. H&E 40×. Proliferation of spindle cells with mild pleomorphism. Few mitotic
ﬁgures were noted.
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a mass compressing on the anterior rectal wall approximately 5 cm in
longest diameter. The patient was treated with imatinib 400 mg daily
for 1 month. Given the short treatment interval there was no change
in the size of the mass. The recurrent tumor was then completely ex-
cised via a rectal approach. Histologically, the tumor was similar to
the initial one and was diagnosed as an EGIST. One month after sur-
gery, in October 2008, sunitinib 50 mg daily was started. At evalua-
tion 3 months after surgery, there were no signs or symptoms of
disease. In May 2009, a CT scan was performed and showed evidence
of recurrence at the rectovaginal septum. A team of gynecologic on-
cologists and surgical oncologists performed a posterior exenteration.
All margins were negative. The patient and her family opted not to
undergo radiation therapy because EGISTs have a low rate of response
to such therapy.
In July 2009, the patient was restarted on imatinib because she did
not tolerate sunitinib and because imatinibwas the only available treat-
ment in Colombia at that time. A positron emission tomography (PET)/
CT scanperformed3 months later did not show any evidence of disease.
In November 2009, however, the patient had another recurrence of her
disease as documented on PET/CT, which revealed a 27-cm pelvic mass
as well as multiple other masses in the retroperitoneum, urinary blad-
der, and anterior abdominal wall.
Supportive care and hospice care were recommended given the
patient's persistent disease despite surgery and treatment withFig. 2. CD117. 40×. Neoplastic cells demonstrating strong diffuse cytoplasmic staining.tyrosine kinase inhibitors. The patient died from multiple organ
failure 6 days after diagnosis of the widespread recurrent disease.
Discussion
GISTs are rare neoplasms and EGISTs are even less common. Fewer
than 10% of all GISTs are located on or near the rectum (Trent and
Benjamin, 2006). These tumors may present as a rectovaginal mass
and may be discovered on routine vaginal examination. GISTs may
arise from the anterior rectal wall, in which case they are true
GISTs, or directly from the rectovaginal septum or the posterior wall
of the vagina, in both cases they are classiﬁed as EGISTs. These latter
tumors (EGISTs) are usually misdiagnosed as myosarcomas or
liposarcomas given the lack of awareness by surgeons, gynecologist
and even by pathologists of EGISTs and their uncommon sites of
appearance (Reith et al., 2000) since they both have the same pattern
arising from stromal gastrointestinal cells in tissues outside the gas-
trointestinal tract.
Pathologically, GISTs, as well as EGISTs, may be as small as a few
millimeters or as large as 35 cm or more. GISTs on the intestinal sero-
sa are frequently found as a single, well-circumscribed nodule, and
GISTs arising from other locations are frequently bulky lesions.
GISTs are composed of a proliferation of spindle cells that mimics
sarcoma. The neoplastic cells express C-Kit (CD117) and CD34 and,
to a lesser degree, h-caldesmon, smooth muscle actin, and S-100
(Fletcher et al., 2002). The DOG 1.1 marker is a fragment of cDNA
encoding a protein whose function is unknown. This marker may be
helpful when a suspected GIST is negative for C-Kit; DOG 1.1 has
high sensitivity (94.4%) in the diagnosis of GISTs and is positive in
30% of cases that are negative for C-Kit (Trent and Benjamin, 2006).
As is the case for patients with GISTs, the prognosis for patients
with EGISTs is predicted by tumor size, mitotic rate, and site of origin
(Reith et al., 2000). In the case of an EGIST, the tumor location often
means that patients do not have any symptoms until the tumor is
already very large. Reith et al. (2000) reported that a mitotic rate of
over 2 mitoses per 50 high-power ﬁelds, high cellularity, and the
presence of necrosis indicates more aggressive EGISTs.
The current treatment for localized disease for GISTs and EGISTs is
to perform a complete surgical resection (Trent and Benjamin, 2006).
However, even after tumor resection with negative margins, high-risk
EGISTs usually recur locally, and local recurrence usually occurs
before distant metastasis becomes evident (Trent and Benjamin,
2006). Standard systemic chemotherapy agents, such as doxorubicin,
epirubicin, docetaxel, and gemcitabine, and radiation therapy have
proven to be of no value in the treatment of GISTs (Trent and
Benjamin, 2006). Neoadjuvant or adjuvant therapy for GISTs and
EGISTs is based on tyrosine kinase inhibitors, either imatinib of
400 mg per day (ﬁrst choice) or sunitinib of 50 mg per day in cycles
of 4 weeks on and 2 weeks off (second choice). Each of these regi-
mens for at least 1 year has been shown to improve disease-free
and overall survival (Trent and Benjamin, 2006). Studies have docu-
mented a 1-year relapse-free survival rate after adequate treatment
with surgery and TKI's of 97%, a 5-year disease-free survival rate of
65%, and a 5-year disease-speciﬁc survival rate of 68% (Trent and
Benjamin, 2006).
Contrast-enhanced CT is the standard imagingmodality for the eval-
uation of GISTs. The typical ﬁndings are a heterogeneously enhancing
exophytic mass. Newer modalities such as ﬂuorodeoxyglucose-PET
help differentiate active tumor from necrotic tissue because the meta-
bolic rate of viable tumor cells (in terms of the standardized uptake
value), which have higher glucose uptake, is higher than the metabolic
rate of necrotic tissue. We reviewed the literature and found reports of
10 patients with rectovaginal EGIST (Nasu et al., 2004; Ceballos et al.,
2004; Weppler and Gaertner, 2005; Takano et al., 2006; Lam et al.,
2006; Nagase et al., 2007; Zhang et al., 2009). The mean age of these
10 patients was 52.8 years (range, 36–75). The mean tumor size was
Table 1
Reported cases of rectovaginal extragastrointestinal stromal tumor.
First author,
reference
No. of
pts.
Age,
years
Tumor
size, cm
Treatment No. of mitosis
per 50 HPF
Necrosis Cd117 Cd34 SMA Ki-67 Outcome
Nasu et al. (2004) 1 54 8.5 Surgery 5–10 + + + + N/A Alive at 13 months
Ceballos et al. (2004) 1 75 4.5 Local excision 12–15 + + + − N/A Recurrence at 7.5 years
Weppler and Gaertner (2005) 1 66 8 Imatinib >5 − + + − N/A N/A
Takano et al. (2006) 1 38 7 Surgery 1–2 N/A + + + N/A Alive at 12 months
Lam et al. (2006) 3 36 4 N/A 15 − + + − N/A Recurrence at 2 years
48 6 N/A 12 + + + − N/A Recurrence at 10 years
61 8 N/A 16 − + + − N/A N/A
Nagase et al. (2007) 2 42 3.5 Local excision b1 + + + − 20–30 Alive at 4 years
66 5 Surgery + imatinib 2–3 − + + − 30 Alive at 6 months
Zhang et al. (2009) 1 42 8 Local excision 10 + + + − 3 Alive, no time report
Muñoz (present case) 1 15 2 Surgery + TKIs* 40 + + − − N/A Recurrence at 4 months,
12 months, and 18 months; DOD
HPF, high-power ﬁeld; N/A, not available; SMA, smooth muscle actin; TKIs, tyrosine kinase inhibitors.
69M. Muñoz et al. / Gynecologic Oncology Reports 5 (2013) 67–696.25 cm (range, 3.5–8.5). Five patients were treatedwith surgery alone,
which ranged from local excision to abdominoperineal resection of the
rectum with posterior vaginal wall resection. One patient had surgery
plus adjuvant therapy with imatinib, and another patient had imatinib
as the only treatment. For three patients, the report did not specify
the treatment. All tumors were positive for CD117 and CD34, but only
two were positive for smooth muscle actin. Three patients had recur-
rent disease, one at 2 years after unspeciﬁed initial treatment, one at
7.5 years after local excision, and one at 10 years after unspeciﬁed ini-
tial treatment. No deaths were reported (Table 1).
The patient in this case report is the youngest patient reported to
date with an EGIST. The patient had a poor response to imatinib and
sunitinib. Her tumor was positive for the new DOG 1.1 marker as
well as C-Kit (CD117) and CD34, conﬁrming the diagnosis of EGIST,
but despite appropriate diagnosis and treatment, the tumor was re-
fractory to tyrosine kinase inhibitors, and the patient died of the dis-
ease. Better understanding of EGISTs and further investigation of the
behavior of these uncommon tumors is needed to achieve accurate
early diagnosis and thereby permit more effective and focused thera-
py for patients with this disease.
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